About: SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets
Creator	Reddy, P Jella, Kishore John, Albin Kandimalla, Ramesh Kumar Jella, Kishore Ramadevi, S Vallamkondu, Jayalakshmi Wani, Willayat Wani, Yousuf
Source	Elsevier; Medline; PMC
abstract	The novel Coronavirus disease of 2019 (nCOV-19) is a viral outbreak noted first in Wuhan, China. This disease is caused by Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2. In the past, other members of the coronavirus family, such as SARS and Middle East Respiratory Syndrome (MERS), have made an impact in China and the Arabian peninsula respectively. Both SARS and COVID-19 share similar symptoms such as fever, cough, and difficulty in breathing that can become fatal in later stages. However, SARS and MERS infections were epidemic diseases constrained to limited regions. By March 2020 the SARS-CoV-2 had spread across the globe and on March 11th, 2020 the World Health Organization (WHO) declared COVID-19 as pandemic disease. In severe SARS-CoV-2 infection, many patients succumbed to pneumonia. Higher rates of deaths were seen in older patients who had co-morbidities such as diabetes mellitus, hypertension, cardiovascular disease (CVD), and dementia. In this review paper, we discuss the effect of SARS-CoV-2 on CNS diseases, such as Alzheimer's-like dementia, and diabetes mellitus. We also focus on the virus genome, pathophysiology, theranostics, and autophagy mechanisms. We will assess the multiorgan failure reported in advanced stages of SARS-CoV-2 infection. Our paper will provide mechanistic clues and therapeutic targets for physicians and investigators to combat COVID-19.
has issue date	2020-06-27(xsd:dateTime)
bibo:doi	10.1016/j.bbadis.2020.165889
bibo:pmid	32603829
has license	no-cc
sha1sum (hex)	096cea27c521159d2378cbdeba2a66dd0d884c7d
schema:url	https://doi.org/10.1016/j.bbadis.2020.165889
resource representing a document's title	SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets
has PubMed Central identifier	PMC7320676
has PubMed identifier	32603829
schema:publication	Biochim Biophys Acta Mol Basis Dis
resource representing a document's body	covid:096cea27c521159d2378cbdeba2a66dd0d884c7d#body_text
is schema:about of	named entity 'cite' named entity 'pathophysiology' named entity 'Disease' named entity 'USFDA' named entity 'diseases' named entity 'CNS' named entity 'therapeutic' named entity 'Autophagy' named entity 'disease' named entity 'SARS-CoV-2' named entity 'Protease Inhibitors' named entity 'HCQ' named entity 'Autophagy' named entity 'approved drugs' named entity 'Repurposed Drugs' named entity 'Coronaviruses' named entity 'Diabetes Mellitus' named entity 'CNS' named entity 'Parkinson's disease' named entity 'ground-glass opacities' named entity 'COVID' named entity 'encephalitis' named entity 'SARS-CoV-2' named entity 'epirubicin' named entity 'diabetes' named entity 'perphenazine' named entity 'virus' named entity 'spike proteins' named entity 'COVID' named entity 'COVID' named entity 'proteases' named entity 'TNF-α' named entity 'SARS-CoV' named entity 'epoprostenol' named entity 'TLR4' named entity 'spike proteins' named entity 'coronaviruses' named entity 'autophagy' named entity 'hypoxemia' named entity 'ion channels' named entity 'viral entry' named entity 'SARS-CoV' named entity 'autopsy' named entity 'spike proteins' named entity 'esterase' named entity 'serine protease' named entity 'SARS-CoV-2' named entity 'chest X-ray' named entity 'ATG1' named entity 'ORFs' named entity 'ribonucleotides' named entity 'SARS-CoV-2' named entity 'autophagy' named entity 'cell death' named entity 'chest imaging' named entity 'encephalomalacia' named entity 'antiviral activity' named entity 'protease' named entity 'hypoglycemic agents' named entity 'Tocilizumab' named entity 'encephalitis' named entity 'virus' named entity 'HAPE' named entity 'quantitative real-time PCR' named entity 'case fatality rate' named entity 'helicases' named entity 'coronaviruses' named entity 'autophagy' named entity 'coronaviruses' named entity 'infection' named entity 'SARS-CoV-2' named entity 'protein' named entity 'conserved residues'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software